Top Markets
Coin of the day
American CryoStem Corporation American CryoStem Corporation

American CryoStem Corporation

CRYO
株式のランク #42083
American CryoStem Corporation (ACSC) specializes in the development,... American CryoStem Corporation (ACSC) specializes in the development, commercialization, and licensing of technologies derived from adipose (fat) tissue, primarily for applications within regenerative and personalized medicine. Among its key offerings is the CELLECT system, designed to streamline tissue sample collection, transportation, and storage for medical practitioners. The company also provides the ATGRAFT service, a comprehensive solution for harvesting, processing, and preserving adipose tissue, enabling physicians to offer patients versatile options for tissue products and cellular banking. Complementing these are ATCELL, a line of proprietary adipose-derived stem cells, and ACSelerat cell culture media, specifically formulated to promote the growth of human stromal cells. Furthermore, American CryoStem extends its expertise through contract manufacturing services for specific formulations, including Autokine-CM, an anti-aging topical product, and a unique autologous skin care range. Founded in 1987, American CryoStem Corporation is headquartered in Eatontown, New Jersey.
株価
$0.0001
最終同期: 2024-04-02
時価総額
$5.03K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 American CryoStem Corporation (CRYO)

カテゴリー

American CryoStem Corporation(CRYO)の利益
2026 時点の利益 TTM: 0
American CryoStem Corporation の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
American CryoStem Corporation の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益